These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37837561)

  • 1. Safety of COVID-19 mRNA vaccination and effects of SARS-CoV-2 infection in children and adults with mast cell disorders.
    Zhu CK; Nguyen A; Prosty C; Gabrielli S; Mulé P; Netchiporouk E; Le M; Zhang X; Shand G; Baum S; Hakroush R; Greenberger S; Ollech A; Miedzybrodzki B; Ben-Shoshan M
    Clin Exp Med; 2023 Dec; 23(8):4937-4942. PubMed ID: 37837561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 Vaccines Are Safely Tolerated in Adolescents with Cutaneous Mastocytosis.
    Yuksel Bulut H; Ulusoy Severcan E; Ertugrul A
    Int Arch Allergy Immunol; 2023; 184(8):776-782. PubMed ID: 37071972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.
    Chu DK; Abrams EM; Golden DBK; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Shaker M; Greenhawt M
    JAMA Intern Med; 2022 Apr; 182(4):376-385. PubMed ID: 35188528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
    Feldstein LR; Britton A; Grant L; Wiegand R; Ruffin J; Babu TM; Briggs Hagen M; Burgess JL; Caban-Martinez AJ; Chu HY; Ellingson KD; Englund JA; Hegmann KT; Jeddy Z; Lauring AS; Lutrick K; Martin ET; Mathenge C; Meece J; Midgley CM; Monto AS; Newes-Adeyi G; Odame-Bamfo L; Olsho LEW; Phillips AL; Rai RP; Saydah S; Smith N; Steinhardt L; Tyner H; Vandermeer M; Vaughan M; Yoon SK; Gaglani M; Naleway AL
    JAMA; 2024 Feb; 331(5):408-416. PubMed ID: 38319331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
    Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
    JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).
    Bonadonna P; Brockow K; Niedoszytko M; Elberink HO; Akin C; Nedoszytko B; Butterfield JH; Alvarez-Twose I; Sotlar K; Schwaab J; Jawhar M; Castells M; Sperr WR; Hermine O; Gotlib J; Zanotti R; Reiter A; Broesby-Olsen S; Bindslev-Jensen C; Schwartz LB; Horny HP; Radia D; Triggiani M; Sabato V; Carter MC; Siebenhaar F; Orfao A; Grattan C; Metcalfe DD; Arock M; Gulen T; Hartmann K; Valent P
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2139-2144. PubMed ID: 33831618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delving Into COVID-19 Vaccination-Induced Anaphylaxis: Are mRNA Vaccines Safe in Mast Cell Disorders?
    Azenha Rama T; Álvarez-Twose I
    J Investig Allergol Clin Immunol; 2021 Apr; 31(2):193-195. PubMed ID: 33574015
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination.
    Li L; Robinson LB; Patel R; Landman AB; Fu X; Shenoy ES; Hashimoto DM; Banerji A; Wickner PG; Samarakoon U; Mancini CM; Zhang Y; Blumenthal KG
    JAMA Netw Open; 2021 Oct; 4(10):e2131034. PubMed ID: 34698847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaphylaxis is a rare reaction in COVID-19 vaccination.
    Bellomo RG; Gallenga CE; Caraffa A; Tetè G; Ronconi G; Conti P
    J Biol Regul Homeost Agents; 2021; 35(3):839-842. PubMed ID: 34105336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
    Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
    BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination.
    Pitlick MM; Joshi AY; Gonzalez-Estrada A; Chiarella SE
    Allergy Asthma Proc; 2022 Jan; 43(1):40-43. PubMed ID: 34983709
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
    Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
    JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
    Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
    Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
    MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
    Jin Z; Wu J; Wang Y; Huang T; Zhao K; Liu J; Wang H; Zhu T; Gou J; Huang H; Wu X; Yin H; Song J; Li R; Zhang J; Li L; Chen J; Li X; Zhang M; Li J; Hou M; Song Y; Wang B; Gao Q; Wu L; Kong Y; Dong R
    J Infect; 2023 Dec; 87(6):556-570. PubMed ID: 37898410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.